Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maria C Schneeweiss

Showing results (1-10 of 28) with videos related to

Pageof 3
Sort By:
JID Innovations : Skin Science From Molecules to Population Health|September 25, 2023
Concepts of Designing and Implementing Pharmacoepidemiology Studies on the Safety of Systemic Treatments in Dermatology PracticeSebastian Schneeweiss, Maria C Schneeweiss
Journal of the American Academy of Dermatology|October 29, 2025
Recognizing and avoiding pitfalls and bias in database researchMaria C Schneeweiss, Arash Mostaghimi, Sebastian Schneeweiss
JAMA Dermatology|January 26, 2022
Venous Thromboembolism in Chronic Inflammatory Skin Diseases-The Need to Consider Bullous Pemphigoid-ReplyMaria C Schneeweiss, Jonathan I Silverberg, Arash Mostaghimi
Pharmacoepidemiology and Drug Safety|December 17, 2022
Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitisPriyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, et al.
Journal of the American Academy of Dermatology|June 4, 2019
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitisMaria C Schneeweiss, Lourdes Perez-Chada, Joseph F Merola
Psychiatric Services (Washington, D.C.)|March 3, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011John G Connolly, Timothy J Toomey, Maria C Schneeweiss
Pediatric Dermatology|November 20, 2022
Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitisPriyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, et al.
Epidemiology (Cambridge, Mass.)|December 15, 2023
Semiparametric Allocation of Subjects to Cohort StrataAlexander M Walker, Massimiliano Russo, Maria C Schneeweiss, et al.
Journal of the American Academy of Dermatology|March 7, 2020
Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based studyMaria C Schneeweiss, Jennifer T Huang, Richard Wyss, et al.
Journal of the American Academy of Dermatology|October 10, 2020
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort studyMaria C Schneeweiss, Seoyoung C Kim, Richard Wyss, et al.
Pageof 3

Showing results (1-10 of 28) with videos related to

Sort By:
Pageof 3
JID Innovations : Skin Science From Molecules to Population Health|September 25, 2023
Concepts of Designing and Implementing Pharmacoepidemiology Studies on the Safety of Systemic Treatments in Dermatology PracticeSebastian Schneeweiss, Maria C Schneeweiss
Journal of the American Academy of Dermatology|October 29, 2025
Recognizing and avoiding pitfalls and bias in database researchMaria C Schneeweiss, Arash Mostaghimi, Sebastian Schneeweiss
JAMA Dermatology|January 26, 2022
Venous Thromboembolism in Chronic Inflammatory Skin Diseases-The Need to Consider Bullous Pemphigoid-ReplyMaria C Schneeweiss, Jonathan I Silverberg, Arash Mostaghimi
Pharmacoepidemiology and Drug Safety|December 17, 2022
Use patterns of systemic immunomodulators in the United States before and after dupilumab approval in adults with atopic dermatitisPriyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, et al.
Journal of the American Academy of Dermatology|June 4, 2019
Comparative safety of systemic immunomodulatory medications in adults with atopic dermatitisMaria C Schneeweiss, Lourdes Perez-Chada, Joseph F Merola
Psychiatric Services (Washington, D.C.)|March 3, 2015
Metabolic monitoring for youths initiating use of second-generation antipsychotics, 2003-2011John G Connolly, Timothy J Toomey, Maria C Schneeweiss
Pediatric Dermatology|November 20, 2022
Longitudinal utilization of systemic immunomodulators before and after dupilumab approval in children with atopic dermatitisPriyanka Anand, Sebastian Schneeweiss, Arash Mostaghimi, et al.
Epidemiology (Cambridge, Mass.)|December 15, 2023
Semiparametric Allocation of Subjects to Cohort StrataAlexander M Walker, Massimiliano Russo, Maria C Schneeweiss, et al.
Journal of the American Academy of Dermatology|March 7, 2020
Serious infection risk in children with psoriasis on systemic treatment: A propensity score-matched population-based studyMaria C Schneeweiss, Jennifer T Huang, Richard Wyss, et al.
Journal of the American Academy of Dermatology|October 10, 2020
Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort studyMaria C Schneeweiss, Seoyoung C Kim, Richard Wyss, et al.
Pageof 3